A new therapeutic clinical trial is now available at Mount Sinai for patients with HPV-related oropharyngeal (tonsil and tongue base) cancer who are eligible to undergo robot-assisted surgery. This study tests a novel vaccine (ADXS11-001) that patients receive during a specific window prior to undergoing surgery.
Icahn School of Medicine at Mount Sinai has received a $3.8 million grant from the American Heart Association (AHA) to promote cardiovascular health through early education and intervention programs targeting high-risk children and their parents in Harlem and the Bronx.
Mount Sinai researchers will study the genes and lifestyles of 600 preschoolers and their parents or guardians who live in these communities, which are associated with high rates of obesity, cardiovascular disease, stroke, and type 2 diabetes. The investigators will track whether the interventions lead to healthier eating habits and additional exercise. They will also examine the participants’ DNA and RNA to understand how genetics plays a role in the development of cardiovascular disease.
A long-standing belief that mammals use the same potent antiviral molecules deployed by plants and invertebrates is being challenged by researchers at Icahn School of Medicine at Mount Sinai.
Their findings, published in the July 10, 2014, issue of Cell Reports, surprised many scientists who assumed that antiviral RNA Interference (RNAi) exists in humans as a natural result of evolution.
Scientists know that human cells, like cells in every living organism with a nucleus, encode and generate small RNAs, which influence our genetics. It is also known that mammals combat viruses with interferons—proteins manufactured by immune cells in response to pathogens.
A novel vaccine that stimulates the body’s immune response has been effective in shrinking tumors in patients with low-grade, B-cell lymphoma. Two patients enrolled in a clinical trial at The Tisch Cancer Institute at the Mount Sinai Health System experienced partial remissions of their disease within six months after completing treatment.
Specific cellular pathways, along which genetic mutations occur, appear to play a key role in the development of autism spectrum disorders (ASD), according to new research from Icahn School of Medicine at Mount Sinai.
The findings, published online in the April 24, 2014, issue of The American Journal of Human Genetics, provide scientists with a better understanding of the complex genetic architecture involved in ASD, which has its roots in early brain development.
More than 300 employees and patients of the Mount Sinai Health System recently gathered in the Guggenheim Atrium to celebrate the 30,000th participant in the BioMe Biobank. The Biobank collects de-identified DNA and plasma used for a variety of research purposes from consenting patients.